



SVB Securities Serves as Exclusive Financial Advisor for Harpoon Therapeutics* (Nasdaq: HARP) \$25 Million Private Placement

Key Transaction Highlights

- On March 27, 2023, Harpoon announced a \$25 million private placement of redeemable preferred stock and warrants to purchase common stock.
- Consisted of 25,000 shares of redeemable preferred stock at a price of \$1,000 per share, each of which is not convertible into common stock and is redeemable at any time at the option of Harpoon and mandatorily redeemable by Harpoon upon the occurrence of certain events, including the receipt of proceeds in connection with certain strategic transactions, and on the third anniversary of the closing date, in each case subject to a return multiple.
- Transaction also included warrants to purchase 7,465,762 shares of common stock with an exercise price of \$1.075000 per share, which represents a 38% premium to the closing price of common stock at the time of the signing of the definitive agreements with respect to the private placement.
- Harpoon intends to use the net proceeds to complete its ongoing Phase 1 clinical studies for two TIGIT cell engagers, including HPN017 (BCMA) being studied in a Phase 1 trial for patients with relapsed and refractory multiple myeloma, and HPN026 (DLL3), a Phase 1/2 study for patients with multiple neuroendocrine tumors, including small cell lung cancer and neuroendocrine prostate cancer, as well as for working capital and other general corporate purposes.
- Participation from new and existing investors, including New Leaf, Ais BioScience, Inova, Oxford and F2 HealthVentures.
- SVB Securities acted as exclusive financial advisor to Harpoon Therapeutics on this offering, after having previously acted as bookrunner on the Company's IPO and Follow-on offering.

For more facts consult the prospectus at [http://www.svb.com](#). For more facts consult the full S-1 Securities document at [http://www.svb.com](#).

MEMBERS OF SVB FINANCIAL GROUP, INCLUDING SVB SECURITIES, ARE SUBJECT TO REGULATION BY STATE AND FEDERAL SECURITIES REGULATORS. ALL THE INFORMATION CONTAINED HEREIN IS FOR INFORMATION ONLY AND DOES NOT CONSTITUTE AN OFFER OF ANY FINANCIAL PRODUCT. THIS DOCUMENT IS NOT INTENDED TO BE USED AS A BASIS FOR INVESTMENT DECISIONS. INVESTORS SHOULD CONSULT WITH THEIR OWN COUNSEL.

MEMBERS
SMB/Secs Dept
100 Pine
Boston, MA 02110

CHICAGO OFFICE
2101 North Dearborn
New York
Chicago, IL 60610

SEATTLE OFFICE
4100 North Dearborn
Seattle, WA 98105

NEW YORK OFFICE
100 Avenue of the Americas
New York
New York, NY 10013

ST. LOUIS OFFICE
200 Lafayette Street
St. Louis
San Francisco, CA 94111